The briefing
A phase 1 study reported that a personalized neoantigen vaccine combined with nivolumab was feasible in patients with platinum‑sensitive high‑grade ovarian cancer. Investigators observed no unexpected safety signals in the small trial.
Original headline
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer